Skip to main content

Curis Inc

CRIS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001108205

No open-market purchases or sales by Curis Inc insiders were filed in the last 90 days; 37 institutions reported holding it in 13F filings for Q2 2026, worth $7.96M in total; Maverick Capital is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Curis Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Curis Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Curis Inc
NameTitleLast reported holdingLast filingFilings, past year
Rubin MarcDirector28,108Jul 9, 20263
Kaitin Kenneth IDirector11,407Jul 9, 20262
Hohneker JohnDirector–Jul 9, 20261
Greenacre Martyn DDirector–Jul 9, 20261
Borgman Anne ElizabethDirector–Jul 9, 20261
Duvall DianthaCFO77,707Jul 9, 20263
Zung Jonathan B.CDO66,667Jul 9, 20263
Dentzer James EPresident & CEO148,730Jul 9, 20263
Hamdy Ahmed MDCMO66,667Mar 23, 20262
Martell RobertHead of Research & Development–Jan 24, 20230
Kunkel Lori AnneDirector–Jan 31, 20220
Steinkrauss WilliamChief Financial Officer–Jan 31, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 1, 2026 (view filing)Mar 311 dayKaitin Kenneth IDirectorPPurchase+10.0K$0.55+$5.50K+710.7%11.4K after
Jan 31, 2022 (view filing)Jan 27-314 daysDentzer James EPresident & CEOSSale−5.50K$3.12−$17.1K−7.8%64.9K after2 lots